Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Aug 5;40(33):4911-4921.
doi: 10.1016/j.vaccine.2022.06.071. Epub 2022 Jul 7.

Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study

Benjamin Wyplosz  1 , Jérôme Fernandes  2 , Ariane Sultan  3 , Nicolas Roche  4 , François Roubille  5 , Paul Loubet  6 , Bertrand Fougère  7 , Bruno Moulin  8 , Didier Duhot  9 , Alexandre Vainchtock  10 , Fanny Raguideau  11 , Joannie Lortet-Tieulent  12 , Emmanuelle Blanc  13 , Jennifer Moïsi  14 , Gwenaël Goussiaume  15
Affiliations
Free article
Observational Study

Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study

Benjamin Wyplosz et al. Vaccine. .
Free article

Abstract

Introduction: The risk of developing pneumococcal infections increases with certain chronic conditions and in immunocompromised patients. We aimed to monitor pneumococcal vaccination coverage in at-risk patients and to examine factors associated with pneumococcal vaccination in France.

Material and methods: In this annual cross-sectional study, at-risk patients were extracted between 2014 and 2018 from the National Health Insurance's (NHI) General scheme's claims database with their vaccine reimbursements. Descriptive analyses and a logistic model were performed to assess the influence of healthcare use and medical and demographic factors on pneumococcal vaccination.

Results and discussion: In 2018, 4.5% of 4,045,021 at-risk adults were up to date with their pneumococcal vaccination. During the study period, the number of patients with chronic medical conditions (86% of 4,045,021) increased by 10.1%, but vaccination coverage decreased from 12.9% to 2.9%. The population with immunocompromised status (14% of 4,045,021) increased by 16.2% and vaccination coverage from 10.3% to 18.8%. Influenza vaccination coverage was much higher and stable (around 45.0%). Factors associated with pneumococcal vaccination were: immunocompromised status vs. having a chronic medical condition (odds ratio [OR] 4.72), influenza vaccination (OR 2.36-3.42), hepatitis B vaccination (OR 2.82), DTPolio vaccination (OR 1.52), ≥5 specialist physicians' visits (OR 1.17), and age above 74 (OR 1.12). Pneumococcal vaccine dispensing was extremely low (median of 9per GP,1per specialist over 9 years) despite frequent healthcare visits.

Conclusion: Pneumococcal and influenza vaccination coverage of adults at risk of pneumococcal disease fell well below public health expectations. Invitations for pneumococcal vaccination should be sent by the NHI to high-risk patients. Patient management protocols should include pneumococcal vaccination. Patients with multiple comorbidities are a high-priority population given the large potential health gains offered by pneumococcal vaccination. Commitment of both scientific societies and health authorities is urgently needed to increase vaccination coverage in at-risk populations.

Keywords: Immunocompromised; Influenza; Pneumococcal infection; SNDS; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Benjamin Wyplosz reports consulting fees from Pfizer; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer, GSK, and Sanofi-Pasteur; Support for attending meetings and/or travel from Pfizer. Jérôme Fernandes reports support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) from HEVA (personal fees); consulting fees from Astellas Pharma and Takeda. Ariane Sultan reports consulting fees (honoraria) from Pfizer, MSD, Lilly, Novo, Amgen, Sanofi, Servier, Urgo, Astra-Zeneca; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer, MSD, Lilly, Novo, Amgen, Sanofi, Servier, Urgo, Astra-Zeneca; Support for attending meetings and/or travel from Lilly, Novo, Sanofi, MSD; Participation on a Data Safety Monitoring Board or Advisory Board (honoraria) from Pfizer, MSD, Lilly, Novo, GSK, Sanofi, Amgen. Nicolas Roche reports grants or contracts (to his research institute) from GSK, Boehringer Ingelheim, Pfizer, Novartis; consulting fees from Boehringer Ingelheim, Novartis, Pfizer, Teva, GSK, AstraZeneca, Chiesi, Sanofi, Zambon; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Novartis, Pfizer, Teva, GSK, AstraZeneca, Chiesi, Sanofi, Zambon.

Publication types